The US Food
and Drug Administration (FDA) has refused to grant a license to pharma major Novartis''s
new painkiller, ''Prexige''.
Basel, Switzerland-based pharmaceutical company received a "not approvable"
rejection letter from the FDA for Prexige, which it had proposed as a once-daily
treatment for patients suffering from osteoarthritic pain.
setback was widely expected after the drug was withdrawn in Australia earlier
this year, after it was blamed for the deaths of two people and for triggering
liver failures that required two others to have liver transplants.